Clinical trial

Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)

NCT04730635

Study summary

ClinicalTrials.gov

Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Donepezil Normalized identity: donepezil View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2021-03-23

PhasePHASE1

Conditions

Alzheimer's Diseaseverified · MONDO: Alzheimer disease

Mild Cognitive Impairmentunresolved

Interventions

DonepezilDRUG · verified · RxNorm: donepezil

PlaceboDRUG

Sponsors & collaborators

Merck Sharp & Dohme LLClead sponsor

Mapped research locations

Long BeachCalifornia, United States1 Fort WorthTexas, United States1 DecaturGeorgia, United States1 Baton RougeLouisiana, United States1 SavannahGeorgia, United States1 AdelaideSouth Australia, Australia1 HeidelbergVictoria, Australia1 BeachwoodOhio, United States1 HallandaleFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04730635 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.